Antiarrhythmic Effects of Statins in Heart Failure

Heart Failure Clinics

Volumn 4, Issue 2, 2008, Pages 187-200

  Sandesara, Chirag M ^a   Roodneshin, Hamid ^a   Sbaity, Salam ^a   Olshansky, Brian ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2,6,6 TETRAMETHYLPIPERIDINE 1 OXYL; ACETYL COENZYME A; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOXIDANT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FARNESYL DIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA 3 FATTY ACID; PLACEBO; POTASSIUM CHANNEL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SODIUM CHANNEL; UNCLASSIFIED DRUG;

ANTIARRHYTHMIC ACTIVITY; CAUSE OF DEATH; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG USE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERLIPIDEMIA; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ARRHYTHMIAS, CARDIAC; BLOOD VESSELS; CLINICAL TRIALS AS TOPIC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ION CHANNELS;

EID: 42149179502     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2008.01.008     Document Type: Review

References (99)

1. Achenbach S., Ropers D., Kohle P., et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 106 (2002) 1077-1082
2. Dilaveris P., Giannopoulos G., and Riga M. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 5 (2007) 227-237
3. Ii M., and Losordo D. Statins and the endothelium. Vascul Pharmacol 46 (2007) 1-9
4. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
5. Fenton II J.W., Jeske W.P., Catalfamo J.L., et al. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry 67 (2002) 85-91
6. Zaca V., Rastogi S., Imai M., et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 50 (2007) 551-557
7. Sola S., Mir M.Q., Lerakis S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
8. Simko F. Statins: a perspective for left ventricular hypertrophy treatment. Eur J Clin Invest 37 (2007) 681-691
9. Lee T.M., Lin M.S., Chou T.F., et al. Effect of simvastatin on left ventricular mass in hypercholesterolemic rabbits. Am J Physiol Heart Circ Physiol 288 (2005) H1352-H1358
10. Penumathsa S.V., Thirunavukkarasu M., Koneru S., et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 42 (2007) 508-516
11. Lee M.H., Cho Y.S., and Han Y.M. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Stem Cells 25 (2007) 1654-1663
12. Yamada T., Node K., Mine T., et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 153 (2007) 1055.e1-1055.e8
13. Pelat M., Dessy C., Massion P., et al. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 107 (2003) 2480-2486
14. Chen J., Nagasawa Y., Zhu B.M., et al. Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats. J Pharmacol Sci 93 (2003) 87-94
15. Hayashidani S., Tsutsui H., Shiomi T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
16. Xing D., Murry D.J., Schmidt M.S., et al. Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity. Heart Rhythm 4 (2007) 629-637
17. Weber K.T., Anversa P., Armstrong P.W., et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20 (1992) 3-16
18. Lee T.M., Chou T.F., and Tsai C.H. Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction. J Mol Cell Cardiol 35 (2003) 1449-1459
19. Shiroshita-Takeshita A., Schram G., Lavoie J., et al. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110 (2004) 2313-2319
20. Kumagai K., Nakashima H., and Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 62 (2004) 105-111
21. Qi X.L., Stewart D.J., Gosselin H., et al. Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Circulation 100 (1999) 1338-1345
22. Mason J.C. The role of statins in vascular protection. Clin Adv Hematol Oncol 5 (2007) 352-354
23. Humphries K.H., Lee M., Sheldon R., et al. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 154 (2007) 908-913
24. Greenwood J., and Mason J.C. Statins and the vascular endothelial inflammatory response. Trends Immunol 28 (2007) 88-98
25. Gelosa P., Cimino M., Pignieri A., et al. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 3 (2007) 567-577
26. Goligorsky M.S., and Wang W. Statins' coat of many colors receives yet another hue. J Am Soc Nephrol 15 (2004) 1098-1100
27. Kayikcioglu M., Can L., Evrengul H., et al. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 90 (2003) 63-72
28. Winlaw D.S., Smythe G.A., and Keogh A.M. Increased nitric oxide production in heart failure. Lancet 344 (1994) 373-374
29. Smith C.J., Sun D., Hoegler C., et al. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res 78 (1996) 58-64
30. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
31. Xie Y.W., Shen W., Zhao G., et al. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro: implications for the development of heart failure. Circ Res 79 (1996) 381-387
32. Recchia F.A., McConnell P.I., Bernstein R.D., et al. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 83 (1998) 969-979
33. Bourcier T., and Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 20 (2000) 556-562
34. Shah R. Endothelins in health and disease. Eur J Intern Med 18 (2007) 272-282
35. Wright J.W., Mizutani S., and Harding J.W. Pathways involved in the transition from hypertension to hypertrophy to heart failure: treatment strategies. Heart Fail Rev (2007) [epub ahead of print]
36. Oi S., Haneda T., Osaki J., et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 376 (1999) 139-148
37. Bauersachs J., Galuppo P., Fraccarollo D., et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 (2001) 982-985
38. Floras J.S. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 22 (1993) 72A-84A
39. Pliquett R.U., Cornish K.G., and Zucker I.H. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 95 (2003) 700-704
40. Bleske B.E., Nicklas J.M., Bard R.L., et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 47 (2006) 338-341
41. Hamaad A., Sosin M., Lip G.Y., et al. Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther 19 (2005) 183-187
42. Vrtovec B., Okrajsek R., Golicnik A., et al. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 11 (2005) 684-690
43. Cygankiewicz I., Wranicz J.K., Zaslonka J., et al. Clinical covariates of abnormal heart rate turbulence in coronary patients. Ann Noninvasive Electrocardiol 8 (2003) 289-295
44. Yeagle P.L., Young J., and Rice D. Effects of cholesterol on (Na+,K+)-ATPase ATP hydrolyzing activity in bovine kidney. Biochemistry 27 (1988) 6449-6452
45. Kutryk M.J., and Pierce G.N. Stimulation of sodium-calcium exchange by cholesterol incorporation into isolated cardiac sarcolemmal vesicles. J Biol Chem 263 (1988) 13167-13172
46. Lijnen P., and Petrov V. Cholesterol modulation of transmembrane cation transport systems in human erythrocytes. Biochem Mol Med 56 (1995) 52-62
47. Lijnen P., and Petrov V. Effect of oral calcium supplementation on intracellular calcium and plasma renin in men. J Endocrinol 146 (1995) 421-429
48. Lijnen P., Petrov V., and Amery A. Pravastatin has no direct effect on transmembrane cationic transport systems in human erythrocytes and platelets. Eur J Clin Pharmacol 47 (1994) 281-283
49. Petrov V.V., Britov A.N., Levitsky D.O., et al. Nonlinear relationship between erythrocyte sodium-lithium countertransport and blood pressure in man. Methods Find Exp Clin Pharmacol 16 (1994) 661-666
50. Ortega A., and Mas-Oliva J. Cholesterol effect on enzyme activity of the sarcolemmal (Ca2+ + Mg2+)-ATPase from cardiac muscle. Biochim Biophys Acta 773 (1984) 231-236
51. Seto S.W., Au A.L., Lam T.Y., et al. Modulation by simvastatin of iberiotoxin-sensitive, Ca2+-activated K+ channels of porcine coronary artery smooth muscle cells. Br J Pharmacol 151 (2007) 987-997
52. Chang H.M., Reitstetter R., Mason R.P., et al. Attenuation of channel kinetics and conductance by cholesterol: an interpretation using structural stress as a unifying concept. J Membr Biol 143 (1995) 51-63
53. Kawabata H., Ryomoto T., and Ishikawa K. Role of cardiac ATP-sensitive K+ channels induced by HMG CoA reductase inhibitor in ischemic rabbit hearts. Hypertens Res 24 (2001) 573-577
54. Tavackoli S., Ashitkov T., Hu Z.Y., et al. Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels. Coron Artery Dis 15 (2004) 53-58
55. Seino S., and Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol 81 (2003) 133-176
56. Tamargo J., Caballero R., Gomez R., et al. Pharmacology of cardiac potassium channels. Cardiovasc Res 62 (2004) 9-33
57. Vaquero M., Caballero R., Gomez R., et al. Effects of atorvastatin and simvastatin on atrial plateau currents. J Mol Cell Cardiol 42 (2007) 931-945
58. Wijffels M.C., and Crijns H.J. Recent advances in drug therapy for atrial fibrillation. J Cardiovasc Electrophysiol 14 (2003) S40-S47
59. 4S Trial Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
60. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
61. De Sutter J., Tavernier R., De Buyzere M., et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36 (2000) 766-772
62. Chiu J.H., Abdelhadi R.H., Chung M.K., et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 95 (2005) 490-491
63. Amar D., Zhang H., Heerdt P.M., et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 128 (2005) 3421-3427
64. Ozaydin M., Dogan A., Varol E., et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 107 (2007) 117-121
65. Marin F., Pascual D.A., Roldan V., et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 97 (2006) 55-60
66. Young-Xu Y., Jabbour S., Goldberg R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379-1383
67. Hanna I.R., Heeke B., Bush H., et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 3 (2006) 881-886
68. Olshansky B. Can lipid-lowering medication reduce the prevalence of atrial fibrillation in patients with left ventricular dysfunction?. Nat Clin Pract Cardiovasc Med 4 (2007) 16-17
69. Patti G., Chello M., Candura D., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114 (2006) 1455-1461
70. Colivicchi V.G., Ficili S., Mocini D., et al. Effects of statin therapy on the recurrence of persistent atrial fibrillation in patients with essential hypertension: a propensity score-adjusted analysis. Eur Heart J 25 (2004) S353
71. Dernellis J., and Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 150 (2005) 1064
72. Engelmann M.D., and Svendsen J.H. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 26 (2005) 2083-2092
73. Siu C.W., Lau C.P., and Tse H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92 (2003) 1343-1345
74. Dotani M.I., Elnicki D.M., Jain A.C., et al. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 86 (2000) 1128-1130
75. Liu T., Li L., Korantzopoulos P., et al. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol (2007) [epub ahead of print]
76. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
77. Studer M., Briel M., Leimenstoll B., et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 165 (2005) 725-730
78. Lorenz H., Junger C., Seidl K., et al. Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction?. Eur Heart J 26 (2005) 1078-1085
79. Vyas A.K., Guo H., Moss A.J., et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 769-773
80. Silva M., Matthews M.L., Jarvis C., et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 29 (2007) 253-260
81. Scirica B.M., Morrow D.A., Cannon C.P., et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 47 (2006) 2326-2331
82. Khush K.K., Waters D.D., Bittner V., et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 115 (2007) 576-583
83. Emberson J.R., Ng L.L., Armitage J., et al. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 49 (2007) 311-319
84. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
85. Goldberger J.J., Subacius H., Schaechter A., et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 48 (2006) 1228-1233
86. Mitchell L.B., Powell J.L., Gillis A.M., et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
87. De Sutter J., Tavernier R., De Bacquer D., et al. Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants. Int J Cardiol 112 (2006) 72-79
88. Dickinson M.G., Ip J.H., Olshansky B., et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 153 (2007) 573-578
89. Fukuta H., Sane D.C., Brucks S., et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112 (2005) 357-363
90. Horwich T.B., Hamilton M.A., Maclellan W.R., et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-224
91. Rauchhaus M., Clark A.L., Doehner W., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42 (2003) 1933-1940
92. Horwich T.B., MacLellan W.R., and Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
93. Kjekshus J. Debate: statins should be used in patients with heart failure. Curr Control Trials Cardiovasc Med 2 (2001) 268-270
94. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
95. Masoudi F.A. Statins for ischemic systolic heart failure. N Engl J Med 357 (2007) 2301-2304
96. Krum H., Ashton E., Reid C., et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 13 (2007) 1-7
97. Riahi S., Schmidt E.B., Christensen J.H., et al. Statins, ventricular arrhythmias and heart rate variability in patients with implantable cardioverter defibrillators and coronary heart disease. Cardiology 104 (2005) 210-214
98. Krum H. UNIVERSE: rosuvastatin has no effect on ventricular remodeling. Presented at the annual meeting of the American College of Cardiology; Atlanta, Georgia 2006.
99. Tavazzi L., Tognoni G., Franzosi M.G., et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6 (2004) 635-641